ASIT biotech - All the bases loaded for ASIT011
ASIT’s FY18 preliminary results were dominated by the initiation of the second Phase III study of gp-ASIT+ where randomisation is now complete. The company’s FY18 operating loss increased slightly to €12.8m compared to FY17. R&D comprised the bulk of operating expense at €10.9m and included €9.9m on the Phase III study. Cash at the end of FY18 and March 19 was €8.5m and €5.9m, respectively, while the previously announced convertible note offering should extend the cash runway from Q319 until Q320.Asit Biotech SA. Asit Biotech SA, formerly Biotech Tools SA, is a Belgium- based company that develops products aimed to prevent negative response of the immune system.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.